Research
Epitranscriptomics & Cancer Adaptation : A.David

Activities

Our research work focuses on the contribution of post-transcriptional mechanisms on cancer cell adaptation, in particular RNA epigenetic & translational control.

More..

Zotero public

Added by pcoopman
Group name EquipePC
Item Type Journal Article
Title [Combining surgery and medical treatments for ovarian cancer: Is there an optimal strategy?]
Creator Thomas et al.
Author Quentin Dominique Thomas
Author Stanislas Quesada
Author Véronique D'Hondt
Author Inès Belaroussi
Author Enora Laas
Author Jean-Marc Classe
Author Michel Fabbro
Author Pierre-Emmanuel Colombo
Abstract The objective of this review is to evaluate the optimal positioning of cytoreduction surgery and perioperative medical treatments in the initial management and relapse of advanced-stage epithelial ovarian carcinoma. In the initial management, primary surgery should be proposed if the absence of tumor residue is feasible with reasonable surgery (extensive surgical resections to be considered and their complications, but also the general condition of the patient). Guidelines recommend 3 to 4 cycles of neoadjuvant chemotherapy before interval surgery for patients not eligible for primary surgery. Late interval surgery (i.e. after?5-6 cycles of chemotherapy) is not a standard of care and should only be proposed in case of poor tumor response after 3-4 cycles and when complete interval surgery seems feasible. At first tumor recurrence in platinum-sensitive patients, a primary cytoreduction surgery can be considered if complete surgery can be managed. Predictive scores (AGO score; i-model score) can be used to select eligible patients. Given the lack of strong evidence, performing cytoreduction surgery at first recurrence in platinum-resistant patients or in the event of subsequent recurrence cannot be recommended. Nevertheless, obtaining a complete surgery in these clinical situations seems to provide a benefit in terms of overall survival and its application should be based on the expertise of specialized teams.
Publication Bulletin Du Cancer
Volume 109
Issue 2
Pages 197-215
Date 2022-02
Journal Abbr Bull Cancer
Language fre
DOI 10.1016/j.bulcan.2021.11.013
ISSN 1769-6917
Short Title [Combining surgery and medical treatments for ovarian cancer
Library Catalog PubMed
Extra PMID: 35027164
Tags Aged, Cancer de l'ovaire, Carcinoma, Ovarian Epithelial, Chemotherapy, Adjuvant, Chimiothérapie néoadjuvante, Chirurgie d'intervalle, Chirurgie de cytoréduction, clinic, Combined Modality Therapy, Cytoreduction Surgical Procedures, Debulking surgery, Drug Resistance, Neoplasm, Facteurs pronostiques, Female, Humans, Interval debulking surgery, Middle Aged, Neoadjuvant chemotherapy, Neoadjuvant Therapy, Neoplasm Recurrence, Local, Ovarian cancer, Ovarian Neoplasms, Patient Selection, Prognostic factors, Therapeutic, Time Factors
Date Added 2022/07/29 - 18:16:44
Date Modified 2022/07/29 - 18:16:44
Notes and Attachments PubMed entry (Attachment)


© Institut de Recherche en Cancérologie de Montpellier - 2011 - Tous droits réservés - Mentions légales - Connexion - Conception : ID Alizés